慧博投研近日发布研究报告，对本土创新药行业进行深度梳理与展望。报告指出，中国创新药产业正以前所未有的速度走向全球舞台，行业迎来系统性重估。研发实力显著提升，结构性挑战仍存中国在研创新药管线数量已达4804个，位居全球第二，标志着从“技术追赶者”向“技术引领者”的转变。然而，创新质量仍需提升——2024年First-in-Class药物占比仅为21.2%，而Me-too药物占比高达69.4%，同质化...
Source Link慧博投研近日发布研究报告，对本土创新药行业进行深度梳理与展望。报告指出，中国创新药产业正以前所未有的速度走向全球舞台，行业迎来系统性重估。研发实力显著提升，结构性挑战仍存中国在研创新药管线数量已达4804个，位居全球第二，标志着从“技术追赶者”向“技术引领者”的转变。然而，创新质量仍需提升——2024年First-in-Class药物占比仅为21.2%，而Me-too药物占比高达69.4%，同质化...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.